According to Boston Scientific, the delay will have no material impact on the company’s fiscal 4Q17 and 2017 results.
Boston Scientific (BSX) announced the delay in the commercialization timelines of BSX’s Lotus devices in Europe and the US on November 28, 2017.
Boston Scientific (BSX) stock fell ~7.5% on November 28, 2017, triggered by the speculation of bad news.
In 3Q17, United Therapeutics’ (UTHR) Remodulin reported revenues of $187.3 million, which reflected ~23% growth on a year-over-year (or YoY) basis and ~19% growth on a quarter-over-quarter basis.
In 3Q17, United Therapeutics’ (UTHR) Tyvaso generated revenues of $88.9 million, a ~13% decline on a year-over-year (or YoY) basis and a ~15% decline on a quarter-over-quarter basis.
In November 2017, the U.S. Food and Drug Administration (or FDA) granted United Therapeutics’ (UTHR) Adcirca Pediatric exclusivity until May 21, 2018.
In 3Q17, United Therapeutics (UTHR) reported revenues of $445 million, a ~9% increase on a year-over-year (or YoY) basis.
Of the four analysts tracking Novartis ADR, two recommend a “buy,” while two recommend a “hold.” None recommends a “sell.”
Novartis reported a 2% YoY rise in revenues at constant exchange rates to ~$12.4 billion in 3Q17. Here, we’ll look at the company’s key developments.
Alcon reported revenues of $1.53 billion in 3Q17, which was 6% higher YoY (year-over-year), compared with $1.44 billion in 3Q16.
Sandoz reported revenues of $2.58 billion in 3Q17, which was 3% higher YoY (year-over-year), compared with $2.52 billion in 3Q16.
This segment contributed ~66.9% of Novartis’s total revenues in 3Q17, reporting ~$8.3 billion, which represents 2% YoY (year-over-year).
Novartis (NVS) gets ~35% of its total revenues from US markets, while over 65% of its total revenues come from outside the US.
Novartis saw revenues of ~$12.4 billion and EPS of $1.29 for 3Q17, which represents a 2% YoY rise, compared with its revenues of ~$12.1 billion in 3Q16.
According to a recent Reuters survey, which included eight investment brokerage firms, six (or 75%) of them have recommended a “hold” for VAR stock.
Varian Medical Systems expects to see fiscal 2018 revenue growth in the range of 2%–4%. Its adjusted diluted EPS (earnings per share) for fiscal 2018 is expected to be $4.20–$4.32.
Varian Medical Systems (VAR) spun off its imaging components business into Varex Imaging in January 2017, thus strengthening its positioning in the oncology market.
In fiscal 4Q17, Varian Medical Systems (VAR) registered a gross profit margin of 42.3% of its total sales, representing a decline of 50 basis points.
Varian’s Oncology segment sales in the Americas rose 2%, whereas order growth in the region rose 1% in 4Q17.
Varian Medical Systems (VAR) received FDA (U.S. Food & Drug Administration) approval in June 2017 for its Halcyon system.